Purpose: This study developed a thermoelectric element (TEE) tourniquet integrating a tourniquet with a temperature control device capable of delivering heat or cold therapy. A randomized controlled trial was conducted to evaluate the effects of the TEE tourniquet on pain, stress, and satisfaction during venipuncture. Methods: In total, 118 hospitalized adults were randomly assigned to heat therapy (40~45°C), cold therapy (0~10°C), thermal grill illusion therapy (alternating heat and cold), or the control group. The TEE tourniquet was applied 10 cm above the puncture site. A temperature intervention began 5 seconds before cannulation and was maintained during the procedure, typically lasting 10 to 30 seconds. The control group received the TEE tourniquet without temperature activation. Outcomes included perceived pain and stress (numerical rating scale), observed pain (Wong-Baker FACES), SpO2, stress index, and participant satisfaction. Results: Significant differences were found among groups in perceived pain (F = 4.82, p = .003), observed pain (F = 5.50, p = .001), and perceived stress (F = 4.72, p = .004). The heat therapy group reported significantly lower pain and stress than the control group. No significant differences were found in SpO₂, the stress index, or satisfaction. Conclusion Heat therapy via the TEE tourniquet significantly reduced venipuncture-related pain and stress. Given its short application time and usability, this device may serve as a clinically useful nursing intervention to improve comfort during invasive procedures.

Background/Aims: The incidence of steatotic liver disease (SLD) is increasing across all age groups as the incidence of obesity increases worldwide. The existing noninvasive prediction models for SLD require laboratory tests or imaging and perform poorly in the early diagnosis of infrequently screened populations such as young adults and individuals with healthcare disparities. We developed a machine learning-based point-of-care prediction model for SLD that is readily available to the broader population with the aim of facilitating early detection and timely intervention and ultimately reducing the burden of SLD. Methods: We retrospectively analyzed the clinical data of 28,506 adults who had routine health check-ups in South Korea from January to December 2022. A total of 229,162 individuals were included in the external validation study. Data were analyzed and predictions were made using a logistic regression model with machine learning algorithms. Results: A total of 20,094 individuals were categorized into SLD and non-SLD groups on the basis of the presence of fatty liver disease. We developed three prediction models: SLD model 1, which included age and body mass index (BMI); SLD model 2, which included BMI and body fat per muscle mass; and SLD model 3, which included BMI and visceral fat per muscle mass. In the derivation cohort, the area under the receiver operating characteristic curve (AUROC) was 0.817 for model 1, 0.821 for model 2, and 0.820 for model 3. In the internal validation cohort, 86.9% of individuals were correctly classified by the SLD models. The external validation study revealed an AUROC above 0.84 for all the models. Conclusions As our three novel SLD prediction models are cost-effective, noninvasive, and accessible, they could serve as validated clinical tools for mass screening of SLD.

Purpose: This study developed a thermoelectric element (TEE) tourniquet integrating a tourniquet with a temperature control device capable of delivering heat or cold therapy. A randomized controlled trial was conducted to evaluate the effects of the TEE tourniquet on pain, stress, and satisfaction during venipuncture. Methods: In total, 118 hospitalized adults were randomly assigned to heat therapy (40~45°C), cold therapy (0~10°C), thermal grill illusion therapy (alternating heat and cold), or the control group. The TEE tourniquet was applied 10 cm above the puncture site. A temperature intervention began 5 seconds before cannulation and was maintained during the procedure, typically lasting 10 to 30 seconds. The control group received the TEE tourniquet without temperature activation. Outcomes included perceived pain and stress (numerical rating scale), observed pain (Wong-Baker FACES), SpO2, stress index, and participant satisfaction. Results: Significant differences were found among groups in perceived pain (F = 4.82, p = .003), observed pain (F = 5.50, p = .001), and perceived stress (F = 4.72, p = .004). The heat therapy group reported significantly lower pain and stress than the control group. No significant differences were found in SpO₂, the stress index, or satisfaction. Conclusion Heat therapy via the TEE tourniquet significantly reduced venipuncture-related pain and stress. Given its short application time and usability, this device may serve as a clinically useful nursing intervention to improve comfort during invasive procedures.

Background/Aims: The incidence of steatotic liver disease (SLD) is increasing across all age groups as the incidence of obesity increases worldwide. The existing noninvasive prediction models for SLD require laboratory tests or imaging and perform poorly in the early diagnosis of infrequently screened populations such as young adults and individuals with healthcare disparities. We developed a machine learning-based point-of-care prediction model for SLD that is readily available to the broader population with the aim of facilitating early detection and timely intervention and ultimately reducing the burden of SLD. Methods: We retrospectively analyzed the clinical data of 28,506 adults who had routine health check-ups in South Korea from January to December 2022. A total of 229,162 individuals were included in the external validation study. Data were analyzed and predictions were made using a logistic regression model with machine learning algorithms. Results: A total of 20,094 individuals were categorized into SLD and non-SLD groups on the basis of the presence of fatty liver disease. We developed three prediction models: SLD model 1, which included age and body mass index (BMI); SLD model 2, which included BMI and body fat per muscle mass; and SLD model 3, which included BMI and visceral fat per muscle mass. In the derivation cohort, the area under the receiver operating characteristic curve (AUROC) was 0.817 for model 1, 0.821 for model 2, and 0.820 for model 3. In the internal validation cohort, 86.9% of individuals were correctly classified by the SLD models. The external validation study revealed an AUROC above 0.84 for all the models. Conclusions As our three novel SLD prediction models are cost-effective, noninvasive, and accessible, they could serve as validated clinical tools for mass screening of SLD.

Background/Aims: The incidence of steatotic liver disease (SLD) is increasing across all age groups as the incidence of obesity increases worldwide. The existing noninvasive prediction models for SLD require laboratory tests or imaging and perform poorly in the early diagnosis of infrequently screened populations such as young adults and individuals with healthcare disparities. We developed a machine learning-based point-of-care prediction model for SLD that is readily available to the broader population with the aim of facilitating early detection and timely intervention and ultimately reducing the burden of SLD. Methods: We retrospectively analyzed the clinical data of 28,506 adults who had routine health check-ups in South Korea from January to December 2022. A total of 229,162 individuals were included in the external validation study. Data were analyzed and predictions were made using a logistic regression model with machine learning algorithms. Results: A total of 20,094 individuals were categorized into SLD and non-SLD groups on the basis of the presence of fatty liver disease. We developed three prediction models: SLD model 1, which included age and body mass index (BMI); SLD model 2, which included BMI and body fat per muscle mass; and SLD model 3, which included BMI and visceral fat per muscle mass. In the derivation cohort, the area under the receiver operating characteristic curve (AUROC) was 0.817 for model 1, 0.821 for model 2, and 0.820 for model 3. In the internal validation cohort, 86.9% of individuals were correctly classified by the SLD models. The external validation study revealed an AUROC above 0.84 for all the models. Conclusions As our three novel SLD prediction models are cost-effective, noninvasive, and accessible, they could serve as validated clinical tools for mass screening of SLD.

Purpose: This study developed a thermoelectric element (TEE) tourniquet integrating a tourniquet with a temperature control device capable of delivering heat or cold therapy. A randomized controlled trial was conducted to evaluate the effects of the TEE tourniquet on pain, stress, and satisfaction during venipuncture. Methods: In total, 118 hospitalized adults were randomly assigned to heat therapy (40~45°C), cold therapy (0~10°C), thermal grill illusion therapy (alternating heat and cold), or the control group. The TEE tourniquet was applied 10 cm above the puncture site. A temperature intervention began 5 seconds before cannulation and was maintained during the procedure, typically lasting 10 to 30 seconds. The control group received the TEE tourniquet without temperature activation. Outcomes included perceived pain and stress (numerical rating scale), observed pain (Wong-Baker FACES), SpO2, stress index, and participant satisfaction. Results: Significant differences were found among groups in perceived pain (F = 4.82, p = .003), observed pain (F = 5.50, p = .001), and perceived stress (F = 4.72, p = .004). The heat therapy group reported significantly lower pain and stress than the control group. No significant differences were found in SpO₂, the stress index, or satisfaction. Conclusion Heat therapy via the TEE tourniquet significantly reduced venipuncture-related pain and stress. Given its short application time and usability, this device may serve as a clinically useful nursing intervention to improve comfort during invasive procedures.

Background/Aims: The incidence of steatotic liver disease (SLD) is increasing across all age groups as the incidence of obesity increases worldwide. The existing noninvasive prediction models for SLD require laboratory tests or imaging and perform poorly in the early diagnosis of infrequently screened populations such as young adults and individuals with healthcare disparities. We developed a machine learning-based point-of-care prediction model for SLD that is readily available to the broader population with the aim of facilitating early detection and timely intervention and ultimately reducing the burden of SLD. Methods: We retrospectively analyzed the clinical data of 28,506 adults who had routine health check-ups in South Korea from January to December 2022. A total of 229,162 individuals were included in the external validation study. Data were analyzed and predictions were made using a logistic regression model with machine learning algorithms. Results: A total of 20,094 individuals were categorized into SLD and non-SLD groups on the basis of the presence of fatty liver disease. We developed three prediction models: SLD model 1, which included age and body mass index (BMI); SLD model 2, which included BMI and body fat per muscle mass; and SLD model 3, which included BMI and visceral fat per muscle mass. In the derivation cohort, the area under the receiver operating characteristic curve (AUROC) was 0.817 for model 1, 0.821 for model 2, and 0.820 for model 3. In the internal validation cohort, 86.9% of individuals were correctly classified by the SLD models. The external validation study revealed an AUROC above 0.84 for all the models. Conclusions As our three novel SLD prediction models are cost-effective, noninvasive, and accessible, they could serve as validated clinical tools for mass screening of SLD.

Purpose: This study developed a thermoelectric element (TEE) tourniquet integrating a tourniquet with a temperature control device capable of delivering heat or cold therapy. A randomized controlled trial was conducted to evaluate the effects of the TEE tourniquet on pain, stress, and satisfaction during venipuncture. Methods: In total, 118 hospitalized adults were randomly assigned to heat therapy (40~45°C), cold therapy (0~10°C), thermal grill illusion therapy (alternating heat and cold), or the control group. The TEE tourniquet was applied 10 cm above the puncture site. A temperature intervention began 5 seconds before cannulation and was maintained during the procedure, typically lasting 10 to 30 seconds. The control group received the TEE tourniquet without temperature activation. Outcomes included perceived pain and stress (numerical rating scale), observed pain (Wong-Baker FACES), SpO2, stress index, and participant satisfaction. Results: Significant differences were found among groups in perceived pain (F = 4.82, p = .003), observed pain (F = 5.50, p = .001), and perceived stress (F = 4.72, p = .004). The heat therapy group reported significantly lower pain and stress than the control group. No significant differences were found in SpO₂, the stress index, or satisfaction. Conclusion Heat therapy via the TEE tourniquet significantly reduced venipuncture-related pain and stress. Given its short application time and usability, this device may serve as a clinically useful nursing intervention to improve comfort during invasive procedures.

Purpose: Pulmonary sarcomatoid carcinoma (PSC) is a rare aggressive subtype of non–small cell lung cancer (NSCLC) with limited therapeutic strategies. We attempted to elucidate the evolutionary trajectories of PSC using multiregional and longitudinal tumor samples. Materials and Methods: A total of 31 patients were enrolled in this study and 11 longitudinal samples were available from them. Using whole exome sequencing data, we analyzed the mutational signatures in both carcinomatous and sarcomatous areas in primary tumors of the 31 patients and longitudinal samples obtained from 11 patients. Furthermore, digital droplet polymerase chain reaction (ddPCR), and programmed death-ligand 1 (PD-L1) immunohistochemistry using the Ventana SP263 assay were performed. Results: TP53 was identified as the most frequently altered gene in the primary (74%) and metastatic (73%) samples. MET exon 14 skipping mutations, confirmed by ddPCR, and TP53 mutations were mutually exclusive; whereas, MET exon 14 skipping mutations frequently co-occurred with MDM2 amplification. Metastatic tumors showed dissimilar genetic profiles from either primary component. During metastasis, the signatures of APOBEC decreased in metastatic lesions compared with that in primary lesions. PSC showed higher MET and KEAP1 mutations and stronger PD-L1 protein expression compared with that recorded in other NSCLCs. Conclusion Decreased APOBEC signatures and subclonal diversity were detected during malignant progression in PSC. Frequent MET mutations and strong PD-L1 expression distinguished PSC from other NSCLCs. The aggressiveness and therapeutic difficulties of PSC were possibly attributable to profound intratumoral and intertumoral genetic diversity. Next-generation sequencing could suggest the appropriate treatment strategy for PSC.

Background/Aims: Chronic hepatitis B (CHB) is related to an increased risk of extrahepatic malignancy (EHM), and antiviral treatment is associated with an incidence of EHM comparable to controls. We compared the risks of EHM and intrahepatic malignancy (IHM) between entecavir (ETV) and tenofovir disoproxil fumarate (TDF) treatment. Methods: Using data from the National Health Insurance Service of Korea, this nationwide cohort study included treatment-naïve CHB patients who initiated ETV (n=24,287) or TDF (n=29,199) therapy between 2012 and 2014. The primary outcome was the development of any primary EHM. Secondary outcomes included overall IHM development. E-value was calculated to assess the robustness of results to unmeasured confounders. Results: The median follow-up duration was 5.9 years, and all baseline characteristics were well balanced after propensity score matching. EHM incidence rate differed significantly between within versus beyond 3 years in both groups (P<0.01, Davies test). During the first 3 years, EHM risk was comparable in the propensity score-matched cohort (5.88 versus 5.84/1,000 person-years; subdistribution hazard ratio [SHR]=1.01, 95% confidence interval [CI]=0.88–1.17, P=0.84). After year 3, however, TDF was associated with a significantly lower EHM incidence compared to ETV (4.92 versus 6.91/1,000 person-years; SHR=0.70, 95% CI=0.60–0.81, P<0.01; E-value for SHR=2.21). Regarding IHM, the superiority of TDF over ETV was maintained both within (17.58 versus 20.19/1,000 person-years; SHR=0.88, 95% CI=0.81–0.95, P<0.01) and after year 3 (11.45 versus 16.20/1,000 person-years; SHR=0.68, 95% CI=0.62–0.75, P<0.01; E-value for SHR=2.30). Conclusions TDF was associated with approximately 30% lower risks of both EHM and IHM than ETV in CHB patients after 3 years of antiviral therapy.